The Checkup by Singlecare

JANUARY 31, 2024

Nocturnal asthma” is when you experience a flare-up of asthma symptoms overnight. It can lead to a loss of crucial shuteye and exacerbate daytime asthma. Much like daytime asthma, common symptoms of nocturnal asthma include coughing, wheezing, shortness of breath, and chest tightness.

105

105

Pharmaceutical Technology

MAY 22, 2023

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma. SinoMab BioScience intends to commence a Phase I clinical trial in China to evaluate SM17’s safety profile.

Immunization 109

Immunization 109

Hospital Pharmacy Europe

AUGUST 8, 2023

Oral dexpramipexole significantly reduced blood absolute eosinophil count (AEC) after 12 weeks compared to placebo in patients with eosinophilic asthma, highlighting the potential value of oral therapy for these patients. According to the Global Initiative for Asthma, asthma affects more than 300 million people worldwide.

Dosage 98

Dosage Hospitals 98

Drug Topics

SEPTEMBER 20, 2023

The phase 3 LIBERTY ASTHMA VOYAGE clinical trial was conducted with the purpose of investigating the effects of the investigational drug and discovering whether it would be a promising option.

98

98

The Checkup by Singlecare

APRIL 12, 2024

Ragweed is the most common allergy culprit, according to the American College of Allergy, Asthma & Immunology. What’s more, allergies can worsen asthma symptoms in individuals with the condition. Allergies, asthma, and eczema often occur together and can be triggered by common allergens.

Immunization 111

Immunization Hospitals 111

Pharmacy Is Right For Me

JANUARY 3, 2024

Linda Gutierrez-Miller, one such student, embarked on a journey to answer these questions, ultimately choosing a career path that aligns with her goals of making a substantial impact and aiding a diverse range of individuals—clinical pharmacy. However, job opportunities opened up that provided me with valuable clinical experience.

Insurance 306

Insurance Communication Patient Care 306

Pharmaceutical Technology

APRIL 26, 2023

AstraZeneca , Teva Pharmaceuticals , and Novartis , and other companies, are expanding their reach in the asthma space by capitalizing on digital technologies to enhance the patient experience. Digital inhalers empower patients to be more proactive in taking control of their asthma,” says Mosnaim.

Medication Delivery 115

Medication Delivery Communication 115

STAT

SEPTEMBER 14, 2023

It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment. The biotech, which is based in Somerville, Mass.,

141

141

STAT

FEBRUARY 20, 2024

The need-to-know this morning Rapt Therapeutics  said the  FDA placed a clinical hold  on its anti-inflammation drug, called zelnecirnon, following a case of liver failure in one patient enrolled in a mid-stage atopic dermatitis study. A separate study in asthma has also been placed on hold.

FDA 107

FDA 107

Pharmaceutical Technology

JANUARY 8, 2023

In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma.

FDA 119

FDA 119

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Labelling 111

Labelling FDA 111

pharmaphorum

AUGUST 10, 2021

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. According to Hinks, “we still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist.

Hospitals 116

Hospitals 116

European Pharmaceutical Review

AUGUST 8, 2023

Tom Keith-Roach, President of AstraZeneca UK announced: “We are pleased that the SMC has now accepted Forxiga (dapagliflozin) for use in patients with chronic heart failure with preserved or mildly reduced ejection fraction and Tezspire (tezepelumab) has been accepted for restricted use in severe asthma within NHS Scotland.”

90

90

Hospital Pharmacy Europe

APRIL 10, 2024

One area of practice in which clinical pharmacists are particularly impactful is respiratory medicine. In December 2023, the European Respiratory Society journal, Breathe , published a paper extolling the many and varied ways in which clinical pharmacists add knowledge and value in respiratory and sleep medicine.

Hospitals 52

Hospitals Patient Care 52

Outsourcing Pharma

NOVEMBER 15, 2021

The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.

52

52

pharmaphorum

MARCH 30, 2022

Data from a massive real-world study of asthma patients has suggested that overuse of inhalers is widespread and leading to an elevated risk of severe exacerbations. The finding was independent of the use of maintenance therapy with inhaled corticosteroids (ICS), used to dampen down the inflammation seen in the lungs of people with asthma.

116

116

STAT

JANUARY 9, 2024

… GSK will purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead , STAT writes. It is currently developing ‘AIO-001’, a treatment for asthma that is ready to enter mid-stage clinical trials.

Vaccines 98

Vaccines 98

pharmaphorum

AUGUST 12, 2022

Patient recruitment specialist Clariness will deploy an app aimed at helping asthma patients monitor environment triggers and report symptoms in the clinical trials its support, thanks to a partnership with digital health firm DailyBreath.

52

52

Hospital Pharmacy Europe

JANUARY 12, 2023

Dupilumab add-on therapy in severe asthma improves the exacerbation rate and disease control according to the findings of a real-world study. Severe asthma occurs when adequate control cannot be achieved by high-dose treatment with inhaled corticosteroids and additional agents (i.e., Dupilumab add-on therapy and asthma outcomes.

Hospitals 59

Hospitals 59

Pharmaceutical Technology

JUNE 9, 2023

Clinical-stage biotech company Upstream Bio has raised $200m in a Series B financing round to advance its UPB-101 to treat allergic and inflammatory diseases. Upstream Bio will use the funds to advance its UPB-101 into Phase II trials to treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

FDA 59

FDA 59

Pharmafile

MARCH 23, 2023

Published date: 23/03/2023 Summary: • Symbicort Turbohaler 200/6 is the first and only approved dual-combination, inhaled corticosteroid + long-acting beta2-agonist (ICS/LABA) reliever therapy (Symbicort Reliever Therapy) to be taken as needed, in response to symptoms in patients with mild asthma aged 12 years and older.0F[1],1F[2],2F[3]

52

52

pharmaphorum

JANUARY 12, 2023

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). An estimated 136 million asthma exacerbations occur globally each year, 10 million of those in the US.

FDA 52

FDA 52

Outsourcing Pharma

JANUARY 13, 2023

The US Food and Drug Administration (FDA) has approved AstraZenecaâs asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.

FDA 59

FDA 59

European Pharmaceutical Review

NOVEMBER 21, 2023

If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future,” GSK’s Chief Executive Officer, Emma Walmsley commented.

112

112

pharmaphorum

NOVEMBER 16, 2022

There’s plenty in the pipeline to entice a potential buyer, however, including several mid-stage clinical candidates, such as EPO inhibitor LKA651 for diabetic retinopathy, Factor B inhibitor iptacopan for AMD, and gene therapy PPY988 for geographic atrophy. Novartis has said it will not comment on market speculation.

124

124

The Checkup by Singlecare

NOVEMBER 20, 2023

DeMarco, MD , a board-certified allergist at Allergy & Asthma Specialists of North Florida. It could take up to three weeks of daily use to notice improvements, per the Mayo Clinic. This helps open up the nasal airways, making it easier to breathe through the nose, according to the Cleveland Clinic.

Mayo Clinic 113

Mayo Clinic Immunization FDA 113

Outsourcing Pharma

JANUARY 16, 2023

A Florida doctor has been sent to prison after submitting a false affidavit claiming she had screened children in a clinical study looking at the effectiveness of drugs given to children with asthma when she had not.

FDA 59

FDA 59

pharmaphorum

MAY 16, 2022

An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial results announced by AstraZeneca and Avillion. Asthma affects as many as 339 million adults and children around the world.

72

72

PharmaShots

MARCH 29, 2023

asthma The recommendation was based on the (PATHFINDER) program incl. Shots: The NICE has issued final draft guidance recommending Tezspire for use within NHS England and NHS Wales as an add-on maintenance therapy in adult and adolescent patients aged ≥12yrs. vs 1.73 & improvements in 2EPs over baseline, incl.

45

45

pharmaphorum

FEBRUARY 26, 2021

AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half of this year, with a broader indication than rival biologic drugs. . There was also a clinically meaningful reduction in 39% of the <150 cells/µL group.

69

69

The Checkup by Singlecare

NOVEMBER 1, 2023

RELATED: Learn how to combine antihistamines for a sneeze-free season Sources Allergy Facts , Allergy & Asthma Foundation of America (2022) Percentage of adults in the United States with allergies who used select allergy medications as of 2021 , Statista Which allergy medicine works the best?

Dosage 111

Dosage Mayo Clinic Hospitals Immunization 111

Pharmaceutical Technology

NOVEMBER 18, 2023

Rilzabrutinib is under clinical development by Principia Biopharma and currently in Phase II for Asthma.

40

40

pharmaphorum

SEPTEMBER 17, 2021

Amgen and AstraZeneca haven’t won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but ICER in the US maintains it will probably not be cost-effective.

FDA 52

FDA 52

The Checkup by Singlecare

OCTOBER 17, 2023

Dry coughs are also associated with irritation from allergies, gastroesophageal reflux disease ( GERD ), bronchitis, and asthma, or may occur as a side effect of certain medications, such as ACE inhibitors. The Cleveland Clinic recommends adding honey and lemon to hot water or herbal teas for increased comfort.

Mayo Clinic 105

Mayo Clinic FDA Hospitals 105

pharmaphorum

NOVEMBER 9, 2022

AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour of approval. The post FDA panel backs AZ’s PT027 asthma rescue drug, but in adults only appeared first on.

FDA 59

FDA Labelling 59

Hospital Pharmacy Europe

SEPTEMBER 11, 2023

Guidance on how global warming can be addressed in clinical practice has been outlined by the European Respiratory Society (ERS) in its latest consensus statement on climate change and respiratory health. We also need to explain the risks to our patients so they can protect themselves from adverse effects of climate change.‘

Hospitals 105

Hospitals 105

Pharmaceutical Technology

FEBRUARY 24, 2023

Amlitelimab is under clinical development by Kymab and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered through intravenous and subcutaneous routes as an infusion.

Immunization 40

Immunization 40